Table 1.
Demographic and Clinical Characteristics of HIV-uninfected and HIV-infected Participants
| HIV-uninfected N= 322 (37.6%) |
HIV-infected N= 534 (62.4%) |
p-value | |
|---|---|---|---|
| Mean Age (years) | 52.6 ± 7.8 | 48.9 ± 6.4 | <0.0001 |
| Race - White (%) | 237 (73.6%) | 324 (60.7%) | 0.0001 |
| BMI (kg/m2) | 26.0 [23.7, 29.1] | 25.1 [22.8, 27.7] | 0.0001 |
| Hepatitis C Virus (HCV) Positive (%) | 28 (8.7%) | 93 (17.4%) | <0.001 |
| Nadir CD4 cell count (cells/μL) | -- | 273 [163, 383] | -- |
| Median CD4 cell count (cells/μL) | -- | 510 [349,693] | -- |
| HIV RNA ≥ 400 copies/mL | -- | 174 (32.7%) | -- |
| DM prevalence (%) | 8.0 | 11.4 | 0.16 |
| Adjusted log HOMA-IR | 1.06 | 1.30 | <0.0001 |
| Mean duration of HIV disease (years) | -- | 10.4 ± 8.2 | -- |
| On Antiretroviral therapy (%) | -- | 498 (93.3%) | -- |
| Nucleoside Reverse Transcriptase Inhibitor (NRTI)* | |||
| Current NRTI | -- | 365 (69.1%) | -- |
| Ever NRTI | -- | 469 (87.8%) | -- |
| Current zidovudine | -- | 113 (21.4%) | -- |
| Ever zidovudine | -- | 340 (63.7%) | -- |
| Current stavudine | -- | 59 (11.2%) | -- |
| Ever stavudine | -- | 282 (52.8%) | -- |
| Protease Inhibitor (PI)** | |||
| Current PI | -- | 214 (40.5%) | -- |
| Ever PI | -- | 367 (68.7%) | -- |
| Current indinavir | -- | 34 (6.4%) | -- |
| Ever indinavir | -- | 172 (32.2%) | -- |
| Current ritonavir, high dose | -- | 3 (0.6%) | -- |
| Ever ritonavir, high dose | -- | 38 (7.1%) | -- |
| Current ritonavir, low dose | -- | 159 (30.1%) | -- |
| Ever ritonavir, low dose | -- | 228 (42.7%) | -- |
| Current lopinavir/ritonavir | -- | 87 (16.5%) | -- |
| Ever lopinavir/ritonavir | -- | 123 (23.0%) | -- |
| Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)‡ | |||
| Current NNRTI | -- | 223 (42.2%) | -- |
| Ever NNRTI | -- | 345 (64.6%) | -- |
Data are expressed as mean ± SD or median [interquartile range]
*
retrovir (AZT), epivir (3TC), didanosine (ddI), stavudine (d4T), abacavir, emtricitabine (FTC), tenofovir
**
saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, darunavir, tipranavir
‡
nevirapine, delavirdine, efavirenz